AzTrials
AzTrials

Adult Spinal Deformity SurgerySALVAGENCT07712666

SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion)

A study testing Cell Saver in people with Adult Spinal Deformity Surgery, run by Mayo Clinic.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The investigator hypothesizes intraoperative salvaged red blood cells are a poor substitute for allogenic packed red blood cell transfusions. In addition to providing inadequate resuscitation, salvaged red blood cells can increase the rate of complications, including postoperative electrolyte abnormalities… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Adult Spinal Deformity Surgery
What is being tested?
Cell Saver
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
146 participants
Where
No sites listed yet
Study dates
1 Nov 2026to 1 Aug 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients >18 years of age undergoing adult thoracolumbar spinal deformity surgery as defined by one or more of the following radiographic criteria: 1) sagittal vertical axis > 15 cm, pelvic incidence (PI) minus lumbar lordosis (LL) > 25°, T1 pelvic angle > 30°, thoracic scoliosis > 70°, thoracolumbar/lumbar scoliosis > 50°, or global coronal alignment > 7 cm; 2) one or more of the following surgical criteria: posterior spinal fusion > 12 levels, 3-column osteotomy (3CO), or anterior-column reconstruction; or 3) age > 65 years and undergoing a minimum of 7 levels of spinal instrumentation surgery (geriatric criteria).

Who cannot join

  • Patients with active spinal infection, neoplasm, acute trauma, neuromuscular etiology, syndromic scoliosis, prisoners, and pregnant patients

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion): A Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing Intraoperative Cell Salvage Versus No Cell Salvage in Adult Spinal Deformity Surgery

The investigator hypothesizes intraoperative salvaged red blood cells are a poor substitute for allogenic packed red blood cell transfusions. In addition to providing inadequate resuscitation, salvaged red blood cells can increase the rate of complications, including postoperative electrolyte abnormalities, thrombocytopenia, anemia, and coagulopathy.

Read the detailed description

The goals of this study would therefore be to:

  1. Determine the impact of intraoperative salvaged red blood cells on resuscitation and whether the return of salvaged red blood cells decreases the amount of intraoperative and postoperative allogenic packed red blood cell transfusions, both in terms of whether any allogenic blood product was provided and the number of units transfused during the hospital stay.
  2. Compare complication rates and other secondary outcomes between patients who receive salvaged red blood cells versus those who did not, including infection, acute kidney injury, thrombocytopenia, liver injury, cardiac events, thrombotic events, pulmonary complications, length of hospital stay, discharge disposition, and 30-day readmission rates.
  3. Determine if there's a threshold of transfused cell salvage blood that may be beneficial (e.g. <300ml) and avoids complications.
Being tested
Cell Saver

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cell SaverDevice

    Using Cell Saver during surgery

Study groups in NCT07712666
Study groupRoleWhat they receive
Cell SaverActive comparatorRandomized to utilize cell savor intraoperatively
Receives: Device: Cell Saver
No Cell SaverNo interventionControl Arm

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure the impact of intraoperative salvaged red blood cells on resuscitation

    Measure the impact of intraoperative salvaged red blood cells on resuscitation and whether the return of salvaged red blood cells decreases the amount of intraoperative and postoperative allogenic packed red blood cell transfusions to confirm if any allogenic blood product was provided.

    Measured: 2 years

Secondary outcomes (2)
  1. Compare complication rates and other secondary outcomes

    Via chart review, compare infection, acute kidney injury, thrombocytopenia, liver injury, cardiac events, thrombotic events, pulmonary complications, length of hospital stay, discharge disposition, and 30-day readmission rates of patients who receive salvaged red blood cells versus those who did not.

    Measured: 2 years

  2. Measure the number of salvaged blood cell units transfused during the hospital stay.

    Measure the number of salvaged blood cell units transfused during the hospital stay.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion1 Aug 2028 (estimated)
  4. Study completion1 Aug 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
146 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07712666
Sponsor's protocol ID
26-004500
Acronym
SALVAGE
Status last verified
Sep 2026
First submitted
1 Jul 2026
Last updated
11 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Hassan FM, Sardar ZM, Lenke LG, Mohanty S, Passias PG, Klineberg EO, Lafage V, Smith JS, Hamilton DK, Gum JL, Lafage R, Mullin J, Kelly MP, Diebo BG, Buell TJ, Kim HJ, Kebaish K, Eastlack R, Daniels AH, Mundis G Jr, Protopsaltis TS, Gupta MC, Schwab FJ, Shaffrey CI, Ames CP, Bess S. Association between cell saver transfusion to estimated blood loss ratio and risk of pulmonary embolism after adult spinal deformity surgery. J Neurosurg Spine. 2026 Jan 16;44(4):564-574. doi: 10.3171/2025.8.SPINE25583.

    PubMed 41569673
  • Mohanty S, Sardar ZM, Hassan FM, Reyes J, Coury JR, Lombardi JM, Lehman RA, Lenke LG. High Cell Saver Autotransfusion is Associated With Perioperative Medical Complications in Adult Spinal Deformity Patients. Spine (Phila Pa 1976). 2023 Sep 1;48(17):1234-1244. doi: 10.1097/BRS.0000000000004743. Epub 2023 Jun 7.

    PubMed 37280746
  • Chung YS, Kim HR, Kang H, Ryu C, Park B, Hong J. Fragility of Red Blood Cells Collected Under Different Conditions With a Cell Saver Device. J Cardiothorac Vasc Anesth. 2019 May;33(5):1224-1229. doi: 10.1053/j.jvca.2018.11.019. Epub 2018 Nov 16.

    PubMed 30655204
  • Gregoretti S. Suction-induced hemolysis at various vacuum pressures: implications for intraoperative blood salvage. Transfusion. 1996 Jan;36(1):57-60. doi: 10.1046/j.1537-2995.1996.36196190516.x.

    PubMed 8607155
  • Sullivan IJ, Faulds JN. Assessment of intra-operative cell salvage haemolysis in the obstetric and orthopaedic clinical setting, in comparison with allogeneic blood. Transfus Med. 2014 Oct;24(5):280-5. doi: 10.1111/tme.12147. Epub 2014 Sep 3.

    PubMed 25185996
  • Liao X, Du K, Zhang J, Meng W, Zuo S, Huang Q, Wang H, Gou D. Red blood cells are damaged by intraoperative blood salvage via Ca2+-dependent and -independent mechanisms. Life Sci. 2019 Jun 15;227:114-121. doi: 10.1016/j.lfs.2019.03.036. Epub 2019 Mar 16.

    PubMed 30890406
  • Falsetto A, Roffey DM, Jabri H, Kingwell SP, Stratton A, Phan P, Wai EK. Allogeneic blood transfusions and infection risk in lumbar spine surgery: An American College of Surgeons National Surgery Quality Improvement Program Study. Transfusion. 2022 May;62(5):1027-1033. doi: 10.1111/trf.16864. Epub 2022 Mar 26.

    PubMed 35338708
  • Liang J, Shen J, Chua S, Fan Y, Zhai J, Feng B, Cai S, Li Z, Xue X. Does intraoperative cell salvage system effectively decrease the need for allogeneic transfusions in scoliotic patients undergoing posterior spinal fusion? A prospective randomized study. Eur Spine J. 2015 Feb;24(2):270-5. doi: 10.1007/s00586-014-3282-2. Epub 2014 Mar 30.

    PubMed 24682378
  • Stone N, Sardana V, Missiuna P. Indications and Outcomes of Cell Saver in Adolescent Scoliosis Correction Surgery: A Systematic Review. Spine (Phila Pa 1976). 2017 Mar 15;42(6):E363-E370. doi: 10.1097/BRS.0000000000001780.

    PubMed 27398896
  • Cheriyan J, Cheriyan T, Dua A, Goldstein JA, Errico TJ, Kumar V. Efficacy of intraoperative cell salvage in spine surgery: a meta-analysis. J Neurosurg Spine. 2020 Apr 3;33(2):261-269. doi: 10.3171/2019.12.SPINE19920. Print 2020 Aug 1.

    PubMed 32244219
  • Lloyd TD, Geneen LJ, Bernhardt K, McClune W, Fernquest SJ, Brown T, Doree C, Brunskill SJ, Murphy MF, Palmer AJ. Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery. Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD001888. doi: 10.1002/14651858.CD001888.pub5.

    PubMed 37681564
  • Nayak P, Hostin R, Klineberg EO, Lafage R, Cardona AE, Oreilly BT, Line B, Passias PG, Bess S, Kebaish K, Lenke LG, Shaffrey CI, Daniels AH, Diebo BG, Ames C, Burton D, Lewis S, Eastlack RK, Mundis GM Jr, Nunley P, Hart RA, Mullin J, Hamilton DK, Lafage V, Gupta M, Kelly MP, Protopsaltis TS, Kim HJ, Schwab F, Smith JS, Gum JL; ISSG. Impact of Complications on DRG Assignment for Adult Spinal Deformity Surgery Using the ISSG-AO Classification System. Spine (Phila Pa 1976). 2026 Aug 15;51(16):1163-1170. doi: 10.1097/BRS.0000000000005566. Epub 2025 Nov 12.

    PubMed 41222566
  • Wick JB, Blandino A, Smith JS, Line BG, Lafage V, Lafage R, Kim HJ, Passias PG, Gum JL, Kebaish KM, Eastlack RK, Daniels A, Mundis G, Hostin R, Protopsaltis T, Hamilton DK, Kelly MP, Gupta M, Hart RA, Schwab FJ, Burton DC, Ames CP, Lenke LG, Shaffrey CI, Bess S, Klineberg E; International Spine Study Group. The ISSG-AO Complication Intervention Score, but Not Major/Minor Designation, is Correlated With Length of Stay Following Adult Spinal Deformity Surgery. Global Spine J. 2025 Mar;15(2):621-632. doi: 10.1177/21925682231202782. Epub 2023 Sep 19.

    PubMed 37725904
  • Klineberg EO, Wick JB, Lafage R, Lafage V, Pellise F, Haddad S, Yilgor C, Nunez-Pereira S, Gupta M, Smith JS, Shaffrey C, Schwab F, Ames C, Bess S, Lewis S, Lenke LG, Berven S; International Spine Study Group. Development and Validation of a Multidomain Surgical Complication Classification System for Adult Spinal Deformity. Spine (Phila Pa 1976). 2021 Feb 15;46(4):E267-E273. doi: 10.1097/BRS.0000000000003766.

    PubMed 33156283
  • Ayala M, Nookala V, Fogel J, Fatehi M. Visual estimation of blood loss versus quantitative blood loss for maternal outcomes related to obstetrical hemorrhage. Proc (Bayl Univ Med Cent). 2023 Mar 13;36(3):341-345. doi: 10.1080/08998280.2023.2187248. eCollection 2023.

    PubMed 37091754

Questions about this trial

What is this clinical trial studying?

A study testing Cell Saver in people with Adult Spinal Deformity Surgery, run by Mayo Clinic.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Laura Westendorf (507-284-8167, westendorf.laura@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure the impact of intraoperative salvaged red blood cells on resuscitation (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07712666, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in